According to a recent LinkedIn post from Cagent Vascular Inc, the company is drawing attention to clinical data on its Serration Remodeling Therapy, or SRT, used in below-the-knee vascular interventions. The post cites imaging from the PRELUDE-BTK study, emphasizing controlled, linear micro-fissures and reporting a final residual stenosis of 21.8% alongside a 1.9% bailout stent rate.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post also highlights a reported 97.7% freedom from clinically driven target lesion revascularization at six months, positioning these outcomes as indicative of a potential new standard of care in peripheral endovascular treatment. For investors, such data points may suggest growing clinical validation for SRT, which could support future adoption, pricing power, and potential revenue growth if the results translate into broader market uptake and guideline recognition.